Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future treatment options with capecitabine in solid tumours.

H Wilke1

  • 1Department of Internal Medicine and Oncology/Hematology, Kliniken Essen-Mitte, Germany. hwilke@kem.telba.de

European Journal of Cancer (Oxford, England : 1990)
|February 14, 2002
PubMed
Summary

Capecitabine, an oral chemotherapy, shows promise in combination therapies for metastatic breast and colorectal cancers. Ongoing trials investigate its efficacy as both a standalone and combination treatment, including adjuvant settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How annulus defects can act as initiation sites for herniation.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2022
Same author

Disc wall structural abnormalities can act as initiation sites for herniation.

European cells & materials·2020
Same author

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

[Current S3 guidelines on surgical treatment of gastric carcinoma].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2011
Same author

[Gastric cancer: current status of multimodality treatment].

Zentralblatt fur Chirurgie·2011
Same author

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Capecitabine is an oral fluoropyrimidine with growing interest in targeted cancer therapy.
  • Taxanes enhance thymidine phosphorylase (TP), supporting rationale for capecitabine combination therapy.
  • Preclinical and Phase I studies indicate synergistic antitumor activity and encouraging efficacy for capecitabine combinations.

Purpose of the Study:

  • To evaluate capecitabine in combination regimens for various cancers.
  • To assess capecitabine's efficacy in metastatic breast and colorectal cancers.
  • To investigate capecitabine as adjuvant therapy for colorectal and breast cancers.

Main Methods:

  • Randomized Phase III trial comparing docetaxel with docetaxel/capecitabine in metastatic breast cancer.

Related Experiment Videos

  • Phase I dose-finding trials for capecitabine/oxaliplatin and capecitabine/irinotecan in metastatic solid tumors.
  • Ongoing X-ACT trial comparing capecitabine with Mayo Clinic regimen in colon cancer patients.
  • Planned Phase III trial comparing capecitabine with doxorubicin/cyclophosphamide or CMF in breast cancer patients.

    • Main Results:

    • Preclinical studies demonstrated synergistic antitumor activity.
    • Phase I studies showed encouraging efficacy for capecitabine combinations.
    • The X-ACT trial aims to demonstrate equivalent disease-free survival for capecitabine.

    Conclusions:

    • Capecitabine shows promise in combination therapies, particularly with taxanes, oxaliplatin, and irinotecan.
    • Capecitabine is being investigated as a potential adjuvant therapy for colorectal and breast cancers.
    • Further clinical trials are ongoing to establish capecitabine's role in various cancer settings.